StockWireNews
Low Float Nasdaq Idea (COEP) Rides A Red Hot Chart While Aiming To Be A Top Global Cell Therapy Market Disruptor
May 30th
Greetings Readers,
Over the years, the global cell therapy market has experienced remarkable growth, with several factors contributing to its expansion.
In 2021, the market was valued at $10.35Bn, and it is projected to reach $60.67Bn by 2030. This growth is driven by the increasing prevalence of chronic disorders and advancements in technology.
The commonness of chronic diseases, such as diabetes, has played a significant role in the growth of the global cell therapy market.
Additionally, with over 900 companies worldwide actively working on advanced therapeutics and approximately 1,000 cell or gene therapy clinical studies in progress, the cell therapy market is displaying explosive growth.
Experts predict that the market could develop up to 60 new cell therapies, providing potential treatments for a wide range of conditions.
Therefore, it is crucial to pay attention to emerging companies in the cell therapy market to identify potential disruptors before Wall Street catches on to what they're up to.
And right now, this specific Nasdaq profile requires immediate attention based on its low float (fewer than 15Mn shares), its red-hot chart, and a couple of key platform potential acquisition press releases.
Drop everything right now and pull up:
*Coeptis Therapeutics Holdings, Inc. (COEP)*
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes.
And right now, COEP has several potential catalysts to familiarize yourself with. Check them out:
No. 1 - A Low Float Provides The Possibility For Explosive Volatility
No. 2 - A Potential Game-Changing Platform Acquisition Could Lead To Expanding Company's Growing Tech Portfolio
No. 3 - If Acquisition Goes Through, COEP Acquire A "Transformational Cell Therapy Platform"
No. 4 - COEP Has Been Picking Up Steam Over The Past Month
But more on those in a second...
The Future Of Medicine Now
Coeptis Therapeutics, Inc. has entered into an exclusive license agreement with the University of Pittsburgh for certain intellectual property rights to technologies developed within research laboratories at the University of Pittsburgh. Chimeric antigen receptors (CARs) are artificial T cell receptors that re-target T cells to specifically recognize and kill tumor cells. The licensing agreement involves a CAR T cell therapy platform called “SNAP CAR” designed to be a universal therapeutic in the treatment of various types of cancer. The SNAP-CAR T cell therapy is currently in preclinical development.
Through the company's subsidiary, Coeptis Pharmaceuticals, they have entered into co-development agreements with VyGen-Bio, led by its team of leading medical researchers at the Karolinska Institutet (KI) based in Stockholm, Sweden, to jointly develop novel natural killer cell-based therapeutics and related diagnostics with an initial focus on the urgent need to improve treatments for cancers that over-express the CD38 protein (CD38+).
COEP's Scientific Collaboration
Coeptis is collaborating with researchers from the University of Pittsburgh and contracted a prominent Clinical Research Organization (CRO) to begin developing the SNAP-CAR T cell therapy with the goal to pursue clinical trials. Coeptis has been assigned the worldwide development and commercialization rights to the licensed technology in the field of human treatment of cancer with antibody or antibody fragments using SNAP-CAR T cell technology.
VyGen-Bio is a discovery-stage, cell-based immunotherapy company focused on the development of transformational technology platforms: GEAR-NK, modified natural killer cell-based therapeutics (NK cells), optimized to be co-administered with targeted antibodies; and, GEAR Diagnostic, a companion diagnostic being developed to select patient populations most likely to benefit from targeted antibody therapies.
CAR T And SNAP-CAR Strategy
The Importance Of CAR T Cell Therapy - Chimeric antigen receptor (CAR) therapy is a new treatment for cancer in which a patient's T cells (a type of immune cell) are genetically engineered to recognize cancer cells to target and destroy them. Cells are extracted from the patient and then genetically engineered to make the CAR and are re-introduced back into the patient. Currently approved CAR T therapies are revolutionizing the treatment of many blood cancers including B cell leukemias and lymphomas by targeting specific proteins found on these cancers, and there is hope in treating additional cancers including solid tumors by having them recognize new targets.
What is SNAP-CAR And How Does It Target Certain Cancers? - Coeptis has licensed a CAR T cell therapy platform called "SNAP-CAR" to be a universal therapeutic. The SNAP-CAR technology is in preclinical development at the University of Pittsburgh. Instead of directly binding to a target on the tumor cell, the CAR T cells are co-administered with one or more antibody adaptors that bind to the tumor cells and are fitted with a chemical group that irreversibly connects them to the SNAP-CAR on the therapeutic cells via a covalent bond. A covalent bond is the highest affinity bond possible, thus this binding is expected to translate to highly potent therapeutic activity.
SNAP-CAR, A Highly Programmable Therapeutic Platform - Pre-clinical studies in mice have demonstrated that by targeting tumors via antibody adaptor molecules, the SNAP-CAR therapy provides a highly programmable therapeutic platform that may present several potential advantages over standard CAR T treatments.
Immunotherapy Challenges
Reducing potential toxicity: The therapeutic activity of the SNAP-CAR T cells can be controlled by the antibody dose, which we envision would allow clinicians to potentially mitigate toxicity from over-activity. We also envision that the immune response against cancer may also be boosted in patients with additional doses of the tagged tumor-specific antibody.
The Goal
Lowering the chance for cancer relapse: Relapse from CAR T cell therapy which often results from the loss or down-regulation of the targeted protein on the cancer, can potentially be avoided by combining SNAP-CAR T cells with antibodies targeting multiple antigens at once.
A Novel Approach
Targeting new cancers: SNAP-CAR T cells are a platform technology that is being developed to be co-administered with tagged, tumor-specific antibodies to potentially target many different tumor types, including hematological malignancies and solid tumors.
GEAR-NK (CD38) Strategy
GEAR-NK (CD38) - The company's science stems from the premise that certain cancer therapies for CD38+ tumors can be enhanced to minimize off-target effects while harnessing the therapeutic impact of NK cells. CD38 is a multifunctional transmembrane glycoprotein that is abnormally overexpressed in a variety of tumor types and is associated with cancer progression.
Immunotherapies, specifically anti-CD38 monoclonal antibodies (mAbs) target the CD38+ cancer cells, but also kill other important innate immune effector cells such as CD38+NK cells that recognize and destroy cancer cells, or virus-infected cells.
How Does CD38 Play An Important Role In Targeting Certain Cancers? - CD38 is a protein receptor overexpressed on certain cancers including hematological malignancies and solid tumors. With the development of anti-CD38 monoclonal antibody therapies (mAbs) designed to bind to CD38 antigen to generate immune-mediated killing, survival outcomes for CD38+ cancers have significantly improved. However, despite the potential benefit of anti-CD38 mAbs, cancers such as multiple myeloma are still considered to be incurable.
Immunotherapy Challenges
Various immunotherapies for CD38+ tumors are designed to find and kill cells that express the CD38 antigen; therefore, CD38+ NK cells are likely to become collateral damage and with their eradication, the overall anti-tumor response is suboptimal.
The Goal
To protect CD38+ Natural Killer (NK) cells so that functional disease-targeting NK cells will not be eradicated, enabling their co-existence with CD38 targeting therapies, and thus allowing for complementary tumor killing and immune surveillance.
A Novel Combinatorial Approach
Modified NK cells that are co-administered with select monoclonal antibodies and/or other CD38 targeting immunotherapies are in pre-clinical development to enhance and maximize tumor kill via combinatorial approaches otherwise not possible.
Get More Details And Sources Here.
-----
As mentioned above, COEP has several potential catalysts to soak in right now. Here they are:
No. 1 COEP Potential Catalyst - A Low Float Provides The Possibility For Explosive Volatility
According to the Yahoo Finance website, COEP has a fairly low float.
The website reports this profile to have approximately 14.58Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could more positive company news in 2023 provide a near term spark?
-----
No. 2 COEP Potential Catalyst - A Potential Game-Changing Platform Acquisition Could Lead To Expanding Company's Growing Tech Portfolio
Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics
Proposed transaction would provide Coeptis with two clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML) and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors
Clinical data from AML Clinical Trial Expected during 2H 2023
WEXFORD, Pa. , April 18, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced it has entered into a binding term sheet with Deverra Therapeutics, Inc. ("Deverra Therapeutics") pursuant to which it has obtained an exclusive right, until August 31, 2023, to negotiate towards the acquisition or license of assets from Deverra Therapeutics related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generation of multiple distinct immune effector cell types, including natural killer (NK) and monocyte/macrophages. Deverra Therapeutics is currently advancing clinical programs investigating these technologies in relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) and patients hospitalized with respiratory viral infections.
The transaction, if finalized, would provide Coeptis with, among other assets, exclusive rights to two FDA approved Investigational New Drug (IND) applications and two Phase 1 clinical trials (NCT04901416, NCT04900454) investigating infusion of DVX201, an unmodified natural killer (NK) cell therapy generated from pooled donor CD34+ cells, in hematologic malignancies and viral infections. In addition, Coeptis would gain access to a highly scalable allogeneic cellular immunotherapy platform that is being developed to generate and deliver off-the-shelf (no HLA matching), cost effective, on demand cell therapies to a broad patient population. Deverra expects phase I clinical trial data from its AML study to be complete during 2H 2023.
Additionally, subject to the successful negotiation and completion of any proposed transaction, Deverra Therapeutics' current Scientific Founder, Chief Scientific Officer and EVP, Research & Development, Colleen Delaney, MD, would be expected to assume the position of Chief Scientific and Medical Officer at Coeptis Therapeutics. Dr. Delaney is a world-renowned expert in cell and gene therapy research with more than 20 years' experience in the translation of scientific discovery to clinical practice, including all aspects of cell therapy product development.
"This transaction would greatly expand Coeptis' technology portfolio by incorporation of a cutting-edge allogeneic cell therapy platform with extensive safety and clinical data and align itself with leading experts in the field of cell and gene therapy," said Dave Mehalick, President and CEO of Coeptis Therapeutics. Mr. Mehalick continued, "The addition of these clinical and pre-clinical immune effector cell programs would significantly diversify our R&D capabilities and bring a clinical pipeline with multiple novel approaches to combination cellular immunotherapy approaches, not yet achieved by others. Importantly, the substantial capabilities of the allogeneic cell therapy platform would open new pathways for Coeptis to consider expanding its cell-based therapies beyond autologous CAR T. We are excited about the possibility of exploring the application of both the SNAP-CAR and GEAR technologies to allogeneic, off-the-shelf immune effector cells. The NK and macrophage (MAC) immune effector cell generation from Deverra's platform combined with Coeptis' target specific CARs has the potential to result in development of allogeneic NK and MAC cell therapies."
...
Read the full article here.
-----
No. 3 COEP Potential Catalyst - If Acquisition Goes Through, COEP Acquire A "Transformational Cell Therapy Platform"
Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment Strategies
Potential acquisition of VyGen-Bio would strengthen Coeptis' oncology pipeline by obtaining exclusive, worldwide ownership rights to GEAR™ Platform and companion diagnostic technologies
WEXFORD, Pa., March 29, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced it has obtained the exclusive right to negotiate towards the acquisition of VyGen-Bio, Inc. or its assets. Coeptis intends to immediately commence its due diligence review of VyGen-Bio's assets, including its IP and know-how related to rights to GEAR™ cell therapy and companion diagnostic platforms, and, depending on the results of its due diligence analysis, turn to negotiation of definitive deal documents. VyGen-Bio's product candidates and platforms were discovered by scientists at the world-renowned Karolinska Institutet in Stockholm, Sweden, including Dr. Arnika Wagner, who is expected to play a key collaborative development role for Coeptis as the Company builds its capabilities to develop treatments for cancer and gains technologies to develop additional cell and gene therapies.
This transaction, if finalized, would expand upon Coeptis' collaboration with VyGen-Bio, which is currently focused on CD38-GEAR-NK, a natural killer (NK) cell therapy for the treatment of CD38+ cancers with an initial focus on multiple myeloma, and CD38-Diagnostic, an in vitro diagnostic tool being developed to help identify cancer patients who may be appropriate candidates for anti-CD38 mAb therapy.
In the event a transaction is consummated, Coeptis would then be in a position to advance the development of various GEAR-engineered cells, including NK cells, T cells, and hematopoietic stem cells, and to pursue development of GEAR-engineered cells for use in combination with mAbs that target a potentially wide range of receptor targets. Additional development options that would be explored could include therapeutic modalities where the antigen-specificity of mAbs is used, such as CAR-T and bispecific antibodies for the treatment of a broad range of hematologic malignancies and solid tumors.
"We believe that the acquisition of VyGen-Bio's GEAR Platform would represent a significant inflection point in the growth of Coeptis and our strategy to be a leader in the development of 'next generation' cell therapy technologies for cancer and other diseases," said Dave Mehalick, President and CEO of Coeptis Therapeutics. "Our vision for GEAR is bold and ambitious, as we believe this novel cell engineering approach protects the integrity, fitness and function of the cell while importantly shielding it from destruction by co-administered mAbs. We believe the GEAR platform offers the potential to not only improve existing cancer therapies, but further expand the use of existing therapies in new indications."
"If we are able to successfully consummate an acquisition transaction, we plan to initially focus on advancing the first GEAR candidate, CD38-GEAR-NK, to the clinic for the treatment of multiple myeloma and to concurrently engage in business development activities to expand the GEAR Platform into new cell therapy products via potential co-development and/or licensing partnerships," Mehalick added.
...
Read the full article here.
-----
No. 4 COEP Potential Catalyst - COEP Has Been Picking Up Steam Over The Past Month
Check out COEP's red-hot chart:
